OncoCyte Stock (NASDAQ:OCX)
Previous Close
$2.11
52W Range
$1.97 - $3.82
50D Avg
$2.65
200D Avg
$2.87
Market Cap
$38.27M
Avg Vol (3M)
$75.56K
Beta
1.00
Div Yield
-
OCX Company Profile
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
OCX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| BDSX | Biodesix, Inc. |
| PRPH | ProPhase Labs, Inc. |
| SERA | Sera Prognostics, Inc. |
| CSTL | Castle Biosciences, Inc. |
| DRIO | DarioHealth Corp. |
| BNR | Burning Rock Biotech Limited |
| INBS | Intelligent Bio Solutions Inc. |
| XGN | Exagen Inc. |
| PSNL | Personalis, Inc. |
| FONR | FONAR Corporation |
| PRPO | Precipio, Inc. |
| ISPC | iSpecimen Inc. |
| STIM | Neuronetics, Inc. |
| SHC | Sotera Health Company |
| TRIB | Trinity Biotech plc |